News
Belite Bio Trial update
The Dragon Study Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects. The closing date for recruitment to the Phase 3 Belite Bio Trial is due to finish end of June 2023 and the age range to extend up to…
Global survey of potential participant perspectives on ocular gene therapy
A research team from Melbourne, Australia, has developed a new questionnaire on gene therapy for inherited retinal disease, known as the Attitudes to Gene Therapy for the Eye (AGT-Eye) survey. They have completed an Australian study, in which almost 700 people with inherited retinal disease provided their views on gene therapies. You can see the…
Retina UK Professional and Annual Conference
Retina UK are holding their Professionals and Annual Conference at the University of Westminster Marylebone Campus, London on Friday 23rd June and Saturday 24th June respectively. These events are face-to-face as well as virtual, and are free to attend. We will have a stand on both days so please come and meet us. Details about…
Points of Light award
We are delighted to announce that the founder of Stargardt’s Connected, Bhavna Tailor, has been awarded the Prime Minister’s Points of Light Award in recognition for setting up Stargardt’s Connected and for helping to raise awareness of Stargardt’s and supporting the community. Stargardt’s Disease is a rare inherited eye condition affecting approximately 1 in 10,000…
Professor Frans P. M. Cremers
Professor of Ophthalmogenetics in the Department of Human Genetics in the Radboudumc in Nijmegen, The Netherlands Professor Cremers obtained his doctorate in Nijmegen in 1991, entitled ‘Positional cloning of a candidate gene for choroideremia gene’, under the supervision of Prof. B. Wieringa and Prof. H-H. Ropers. He headed the Division of Molecular Genetics from 1992…